Completed PHASE1 INTERVENTIONAL NCT00620425

A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs

A Single-Center, Open-label, Single-Arm Study to Evaluate the Effects of Repeat Doses of Subcutaneously Delivered Sumatriptan Via the Intraject System of Local Injection Site Signs in Healthy Adult Subjects.

Sponsor: Zogenix, Inc.

Conditions Healthy

Interventions Sumatriptan

Updated 9 times since 2017 Last updated: May 8, 2023 Started: Dec 31, 2007 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Zogenix, Inc. and has accumulated 9 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2023 — Jun 2023 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zogenix, Inc.

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.